There is a need for further studies involving larger sample sizes in various geographical regions of the Indian subcontinent to draw more conclusive evidence of HER2 expression in CRC. This can potentially lead to the application of therapies involving trastuzumab and/or small inhibitors of ErbB-2 in HER2-positive CRC patients. This evidence concerns the gene ERBB2 and colorectal carcinoma.